Innate Pharma SA Finance Income
Innate Pharma SA (IPHA) reported Finance Income of EUR 7.95 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Income Statement › Other Income
ifrs-full:FinanceIncome · last filed 2026-04-01
| Period end | Finance Income 6 month | Finance Income 12 month |
|---|---|---|
| 2025-12-31 | 7.95M EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | 6.89M EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | 6.08M EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | 3.61M EUR 6-K · filed 2025-09-17 | |
| 2023-12-31 | 6.93M EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 3.08M EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | 4.78M EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 4.05M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | 6.34M EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | 3.49M EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | 4.86M EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | 2.45M EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | 11.27M EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 6.00M EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 2.50M EUR 20-F · filed 2020-04-24 |